Citation:
Xu R, Fathima P, Strunk T, de Klerk N, Snelling TL, Richmond PC, Keil AD, Moore HC. RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study. BMC Pediatr. 2020;20(1).
Keywords:
High-risk; Infants; Neonatal intensive care unit; Palivizumab; Respiratory syncytial virus.
Abstract:
The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined the level of palivizumab use in a cohort of high-risk infants in Western Australia.
RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study
The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.